
National Lab Companies Move Quickly to Market Fujirebio’s Lumipulse for Earlier Alzheimer’s Detection
The new blood-based assay avoids painful lumbar punctures and may quicken Alzheimer’s diagnoses

The new blood-based assay avoids painful lumbar punctures and may quicken Alzheimer’s diagnoses

The assay was widely used during the early months of COVID-19 and was a significant source of revenue growth for a time

The early focus is on drug applications, but it could spread to the laboratory test approval process as well

The legal strategy of the ACLA—and some political luck—prevailed in the lawsuit against LDT oversight

Two OIG advisory opinions guide laboratories that want to work with pharma or medical device companies on expanded testing